Zacks Research Issues Positive Outlook for BIO Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities research analysts at Zacks Research increased their Q1 2028 earnings estimates for Bio-Rad Laboratories in a research report issued to clients and investors on Tuesday, August 25th. Zacks Research analyst Team now anticipates that the medical research company will earn $2.26 per share for the quarter, up from their previous forecast of $1.96. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.28 per share.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Tuesday, August 4th. The medical research company reported $2.62 EPS for the quarter, beating the consensus estimate of $1.75 by $0.87. The firm had revenue of $651.00 million for the quarter, compared to analysts’ expectations of $623.99 million. Bio-Rad Laboratories had a net margin of 8.59% and a return on equity of 3.54%. Bio-Rad Laboratories’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter last year, the company earned $2.61 EPS.

Several other brokerages have also weighed in on BIO. Royal Bank Of Canada upped their price objective on Bio-Rad Laboratories from $320.00 to $370.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Wells Fargo & Company boosted their price target on shares of Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of Bio-Rad Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research report on Monday, August 17th. Finally, Citigroup raised their price objective on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Bio-Rad Laboratories has an average rating of “Hold” and a consensus target price of $343.33.

Bio-Rad Laboratories Trading Up 0.2%

Shares of NYSE:BIO opened at $391.29 on Thursday. The firm has a market cap of $10.46 billion, a P/E ratio of 47.43 and a beta of 1.06. The company has a current ratio of 3.14, a quick ratio of 2.33 and a debt-to-equity ratio of 0.11. Bio-Rad Laboratories has a twelve month low of $236.73 and a twelve month high of $393.10. The company has a 50 day moving average of $322.01 and a 200-day moving average of $294.60.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several large investors have recently made changes to their positions in the company. Hollencrest Capital Management acquired a new position in shares of Bio-Rad Laboratories during the 1st quarter valued at about $28,000. Danske Bank A S acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter worth approximately $30,000. Geneos Wealth Management Inc. raised its stake in Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $47,000. Finally, Farther Finance Advisors LLC boosted its holdings in Bio-Rad Laboratories by 76.9% in the 4th quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 80 shares during the period. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.